

ORGANIZED BY:



# ECHSA

VIRTUAL EVENT

2022  
ANNUAL  
MEETING

EUROPEAN  
CONGENITAL  
HEART SURGEONS  
ASSOCIATION



**MAY**  
**6-7**  
**ATHENS**  
**GREECE**

## FINAL PROGRAM



Dear ECHSA Members and friends,

During planning of this year's meeting, we had hoped to be able to gather in the traditional fashion with a physical meeting in springtime Athens. But we also planned for a hybrid event with a possibility to participate on the same virtual platform, that worked so well last year. This we did realizing, that Covid and travel restrictions could still be with us.

As registrations for the physical meeting were slow to come and many of the invited faculty responded that they would only participate virtually, we asked you last week to let us know, if you intended to join the meeting in Athens. Your answers made it clear that the meeting would not have a sufficient number of attendees to be sustainable and to provide the physical experience of meeting everyone in scientific and social discourse, as we all desire. It is evident that concerns regarding the uncertainties of the pandemic and world affairs still loom.

For this reason, the ECHSA Board has decided that the ECHSA Annual Meeting 2022 will have to be in a virtual form only. This necessary decision was made with great regret, as ECHSA meetings are traditionally fruitful, informal gatherings of friends in which scientific exchanges flourish.

The Scientific Program was changed to a shorter version, more suitable for the virtual format, while at the same time keeping an exciting scientific content, the customary framework of our Congresses, and of course our ECHSA business meeting in the Spring, as stipulated by our bylaws. Professor Bertsimas of MIT, a world expert on Artificial Intelligence, will lecture on the amazing innovative uses of Machine Learning in Pediatric Cardiac Surgery. Professor Robert Anderson will lecture on the interaction of Cardiac Morphology with modern imaging technology. Other lectures by the Presidents of our collaborating Scientific Societies (CHSS, WSPCHS, and AEPC) will complement your research and clinical contributions, in the form of video, oral or e-poster presentations, and best-worst case reports.

We are also proud to host two Special Sessions, dedicated to honoring two long-time colleagues and friends for their immense contributions: Bohdan Maruszewski and Marshall L. Jacobs, both of whom are stepping down this year from their important roles as ECHSA Database Committee Chair and WJPCHS Editor, respectively. Furthermore, we have planned State-of-the-Art Sessions, on the topics of DORV, and the Lymphatic system, where leading experts will be sharing their insight and experience.

The Meeting will be concluded, as customary, with reports by the Database and Research Committees providing updates on the exciting developments and achievements of this past year, the ECHSA Presidential Address, and, lastly, our ECHSA Business Meeting.

We welcome you all to this experience, and thank you for your continued support of ECHSA and its activities.

With our best regards,



**Morten Helvind**  
*ECHSA Secretary General  
Chair of the  
ECHSA 2022 Annual Meeting  
Organizing Committee*



**George Sarris**  
*ECHSA President  
ECHSA 2022 Annual Meeting  
Local Host*

p. 2 Welcome Messages

### About ECHSA

p. 4 ECHSA Aims & Contacts

p. 4 ECHSA Events

p. 4 ECHSA Leadership

p. 5 ECHSA Committees

p. 6 ECHSA Membership

p. 6 ECHSA Contributors

### Scientific Programme

p. 8 Overview

p. 10 Friday | 6 May 2022

p. 13 Saturday | 7 May 2022

p. 16 Oral presentations

p. 17 e-Poster presentations

p. 18 Faculty List

### Sponsors' Section

p. 19 Sponsors' acknowledgement

p. 20 Industry profiles

p. 21 Industry sponsored presentations





### Events

ECHSA organizes its Annual Scientific Meeting each Spring, and may also organize additional specialized courses and seminars. Every 4 years since 2004, ECHSA has been organizing a Joint Meeting with the Congenital Heart Surgeons' Society ([www.chss.org](http://www.chss.org)), which is ECHSA's "sister" association in the United States.

Traditionally, ECHSA Meetings were open only to the Members of the Association. However, since the 2017 Annual Meeting held in Leicester, UK, and onwards, all ECHSA Meetings are open to the entire congenital heart scientific community. This creates a unified platform for everyone involved in the care of patients with congenital heart disease to participate and exchange experiences: cardiologists, cardiac surgeons, anaesthetists, intensivists, pathologists, researchers, perfusionists, nurses and medical technicians, are all most welcome.

The Scientific program includes "best and worst" case presentations and discussions, surgical video sessions, pro and con controversy discussions, advanced clinical research presentations, industry workshops and specialized invited lectures.

In response to increased demand for virtual educational programs, as the COVID pandemic remains an inhibitory factor for hosting physical events, the ECHSA has set up a platform with its Secretariat, Convin SA, to host its events for as long as there are related restrictions. The platform is a state-of-the-art experience by itself, offering enhanced interaction opportunities and various branding and placement options. In this context, ECHSA has organized its 2021 Annual Meeting in a virtual environment on 19-20 June 2021. In 2022, though organized as a hybrid event, the Annual Meeting is taking place once again in virtual format on 6-7 May. More information is posted on the ECHSA official website [www.echsa.org](http://www.echsa.org)

### Aims & Contacts

The aim of the European Congenital Heart Surgeons Association ([www.echsa.org](http://www.echsa.org)) is to advance surgery for congenital heart defects, to improve the treatment of patients with congenital heart disease in Europe, and by all means promote the research and treatment related directly or indirectly to congenital heart diseases, irrespective of the patient's race, religion, origin, wealth, or other discriminative factors. For realization of this aim, the Association carries on research of surgery for congenital heart diseases, and organizes courses, seminars and conferences for congenital heart disorders. To support these [www.echsa.org](http://www.echsa.org) activities, the Association receives donations, grants and sponsorships.

### ECHSA Association Management Company & Core-PCO



**CONVIN S.A.**  
29 K. Varnali street, 152 33 Chalandri, Athens, Greece  
T: +30 210 6833600 (call centre)  
F: +30 210 6847700  
ECHSA e: [secretariat@echsa.org](mailto:secretariat@echsa.org)  
ECHSA w: [www.echsa.org](http://www.echsa.org)

Meeting e: [info-meeting@echsa.org](mailto:info-meeting@echsa.org)  
2022 Meeting w: [www.echsa2022.org](http://www.echsa2022.org)  
Corporate e: [info@convin.gr](mailto:info@convin.gr)  
Corporate w: [www.convin.gr](http://www.convin.gr)

### Leadership

The business of the Association is taken care by the **Board**, which is elected in the annual general meeting.

Operation of the ECHSA Congenital Database and coordination of ECHSA's research projects are handled respectively by the **Database Committee** and the **Research Committee**.

Membership and admissions to the Association is supervised by the **Membership Committee**.

## ECHSA Board

President	<b>George Sarris</b> (ATHENS, GREECE)
Secretary General	<b>Morten Helvind</b> (COPENHAGEN, DENMARK)
Treasurer	<b>Ilkka Mattila</b> (HELSINKI, FINLAND)
Member	<b>Sertaç Çiçek</b> (ISTANBUL, TURKEY)
	<b>Jürgen Hörer</b> (MUNICH, GERMANY)
	<b>Jeffrey Jacobs</b> (ST. PETERSBURG, UNITED STATES)
	<b>Attilio Lotto</b> (LIVERPOOL, UNITED KINGDOM)
	<b>Rudolf Mair</b> (LINZ, AUSTRIA)
	<b>Vladimiro Vida</b> (PADOVA, ITALY)

## ECHSA Congenital Database Committee

Chair:	<b>Bohdan Maruszewski</b> (WARSAW, POLAND) - DATABASE DIRECTOR
Co-Chair (ex-officio):	<b>George Sarris</b> (ATHENS, GREECE)
Treasurer (ex-officio):	<b>Ilkka Mattila</b> (HELSINKI, FINLAND)
Technical Director:	<b>Zdzislaw Tobota</b> (WARSAW, POLAND)
Members:	<b>Boulos</b> (ASFUR ST. AUGUSTIN, GERMANY)
	<b>Tjark Ebels</b> (AMSTERDAM, NETHERLANDS)
	<b>Claudia Herbst</b> (VIENNA, AUSTRIA)
	<b>Jürgen Hörer</b> (MUNICH, GERMANY)
	<b>Andrzej Kansy</b> (WARSAW, POLAND)
	<b>Attilio Lotto</b> (LIVERPOOL, UNITED KINGDOM)
	<b>Vladimiro Vida</b> (PADOVA, ITALY)
Associate Members:	<b>Kisaburo Sakamoto</b> (SHIZUOKA, JAPAN)
	<b>Haibo Zhang</b> (SHANGHAI, CHINA)
STS Representative:	<b>Jeffrey Jacobs</b> (ST. PETERSBURG, UNITED STATES)
AEPC Representative:	<b>Thomas Krasemann</b> (ROTTERDAM, NETHERLANDS)

## ECHSA Research Committee

Chair:	<b>George Sarris</b> (ATHENS, GREECE)
Co-Chair:	<b>Giovanni Stellin</b> (PADOVA, ITALY)
Secretary:	<b>Vladimiro Vida</b> (PADOVA, ITALY)
Members:	<b>Attilio Lotto</b> (LIVERPOOL, UNITED KINGDOM)
	<b>Anastasios Polimenakos</b> (AUGUSTA GA, UNITED STATES)
	<b>James St. Louis</b> (KANSAS CITY MO, UNITED STATES)
	<b>Eleftherios Protopapas</b> (ATHENS, GREECE)

## ECHSA Membership Committee

Chair (ex-officio):	<b>Morten Helvind</b> (COPENHAGEN, DENMARK)
	<b>Julie Cleuziou</b> (MUNICH, GERMANY)
	<b>Vladimir Ilyin</b> (MOSCOW, RUSSIAN FEDERATION)
	<b>Matej Nosal</b> (BRATISLAVA, SLOVAKIA)
	<b>Massimo Padalino</b> (PADOVA, ITALY)
	<b>Catharina van Doorn</b> (LONDON, UNITED KINGDOM)
	<b>Haibo Zhang</b> (SHANGHAI, CHINA)

## ECHSA Membership

ECHSA Members are distinguished pediatric heart surgeons from all over Europe and the world. Membership is constantly expanding, representing more and more countries across the globe. At the moment, there are **111 members** from **30 countries**. During this Meeting, **10 more members** will be introduced to ECHSA.



The ECHSA Membership List is available on the Association's website:  
<http://www.echsa.org/members-list>

## ECHSA Contributors

In addition to the scientific meetings organized by ECHSA on a regular basis, the Association's contribution to the advancement of Paediatric Heart Surgery revolves around two major projects: **ECHSA Congenital Database (ECDB)** and **ECHSA Multi-Institutional Studies**.

ECHSA collaborates closely with the most significant scientific associations in the field of congenital heart disease, with which joint meetings are frequently held:

- **CHSS** (Congenital Heart Surgeons' Society)
- **WSPCHS** (World Society for Paediatric and Congenital Heart Surgery)
- **AEPC** (Association for European Paediatric and Congenital Cardiology)

The official Journal of ECHSA is the **World Journal for Paediatric and Congenital Heart Surgery** (WJPCHS, <http://journals.sagepub.com/home/pch>), which is also the official journal of CHSS and WSPCHS.

## ECHSA Congenital Database

Participation in the ECHSA Congenital Database is a major benefit of Membership. An important aim of the founding members of ECHSA was to collect data on the outcomes of Congenital Heart Surgery procedures across Europe, thereby making possible comparison of results and identification of risk factors, as well as targeting research activities. This required good quality data obtained on a large scale from numerous European congenital cardiothoracic surgery units, as well as data validation and verification. Such data collection allows risk stratification and helps define optimal surgical treatment for certain subsets of patients. It is hoped that this effort will contribute to improved early and late survival, as well as improved quality of life for surgically treated patients with congenital heart disease across Europe.

The European Congenital Heart Surgeons Foundation, which was established in 1992 and obtain legal entity as the European Congenital Heart Surgeons Association in 2003, created the European Congenital Heart Defects Database (ECHDD), precursor of today's ECHSA Congenital Database (ECDB).

Today, the immediate aim of the ECDB is to collect data relating to treatment of patients with congenital heart disease, including diagnoses, risk factors, surgical and other procedures, as well as early and, eventually, long-term outcome.

The ECDB is accessed on an Institutional Level, with an annual fee required. There are currently **408 registered centers from 86 countries**.



Further information and documentation are available at the dedicated ECHSA Congenital Database website  
<http://echsacongenitaldb.org/>



### ECHSA Multi-Institutional Studies

ECHSA Multi-Institutional Studies are planned and organized by initiatives from individual Members, and coordinated by the ECHSA Research Committee. The research plans are discussed, refined, approved, and their progress monitored at the Annual Meetings. They constitute an extremely powerful way of pooling together the experiences of a great number of centers on the treatment of important and often rare conditions. The ECHSA Multi-Institutional Studies have produced outstanding research papers, published in prestigious international peer-reviewed journals. There are always several ongoing multi-institutional studies, which, upon completion, will be presented at major scientific meetings and then submitted for publication.



Published and Ongoing Studies, as well as New Proposals and Ongoing Joint Studies are available on the ECHSA website

<http://www.echsa.org/scientific-projects>



## Friday, 6 May 2022

12:00–13:10	<b>WELCOME AND SESSION 1: ABSTRACT PRESENTATIONS</b>
13:20–13:50	<b>INVITED HONORARY LECTURE 1:</b> Artificial Intelligence in Medicine
14:00–14:30	<b>SESSION 2: SPECIAL SESSION – HONORING BOHDAN MARUSZEWSKI</b> More than 20 years of ECHSA Database Research
14:40–15:00	<b>INDUSTRY SPONSORED PRESENTATION 1</b>
15:10–15:30	<b>INDUSTRY SPONSORED PRESENTATION 2</b>
15:40–16:40	<b>SESSION 3: Surgical Management in DORV</b>
16:50–17:20	<b>SESSION 4: SPECIAL SESSION – HONORING MARSHALL LEWIS JACOBS</b> The WJPCS Editor's Perspective
17:30–18:30	<b>SESSION 5: ABSTRACT PRESENTATIONS</b>
18:40–19:10	<b>INVITED HONORARY LECTURE 2</b>

## Saturday, 7 May 2022

12:00–13:00	<b>SESSION 6: ABSTRACT PRESENTATIONS</b>
13:10–13:40	<b>INVITED HONORARY LECTURE 3:</b> Three-dimensional understanding of congenital cardiac malformations – The new gold standard
13:50–15:00	<b>SESSION 7: Lymphatic system and intervention in congenital heart disease</b>
15:30–16:10	<b>ECHSA COMMITTEE REPORTS &amp; CLOSING SESSION</b>
16:20–17:20	<b>ECHSA BUSINESS MEETING</b>

Time indicated in

**EEST**  
(UTC+3h)







# Detailed Programme

# Detailed Programme

## DAY 1 | Friday | 6 May 2022

Time indicated in EEST (UTC+3h)



**ECHSA ANNUAL MEETING**  
VIRTUAL EVENT 2022

12:00-13:10



### WELCOME AND SESSION 1: ABSTRACT PRESENTATIONS

#### 12:00-12:10 WELCOME MESSAGES

**George Sarris** | Greece | ECHSA President

**Morten Helvind** | Denmark | ECHSA Secretary, Chair of the 2022 Meeting Organizing Committee

#### 12:10-13:10 Abstract Presentations

Chairs: **Ilkka Mattila** | Finland, **Sara C. Arrigoni** | Netherlands, **Attilio Lotto** | United Kingdom

**OP01** *Survival and re-operations following repair of truncus arteriosus - A population-based retrospective follow-up study*

**Mari Ylinen** | Finland

**OP02** *Mitral valve replacement in neonates and infants: a single-center experience*

**Illya Yemets** | Ukraine

**OP03** *Factors affecting Truncus arteriosus repair in the modern era*

**Attilio Lotto** | United Kingdom

**OP04** *Quality of life in failing Fontan patients supported with the novel EXCOR Venous Cannula: experience from the first two cases*

**Oliver Miera** | Germany

13:10-13:20



### Intermission

13:20-13:50



### INVITED HONORARY LECTURE 1: Artificial Intelligence in Medicine

Panelists: **Jose Fragata** | Portugal, **Bohdan Maruszewski** | Poland, **Jeffrey Jacobs** | USA

Introduction by **George Sarris** | Greece

Speakers: **Dimitris Bertsimas** | USA

13:50-14:00



### Intermission



14.00–14.30



**SESSION 2: SPECIAL SESSION – HONORING BOHDAN MARUSZEWSKI**  
More than 20 years of ECHSA Database Research

Chairs: **George Sarris** | Greece, **Jose Fragata** | Portugal, **Claudia Herbst** | Austria

Introduction by: **Jeffrey Jacobs** | USA

Speaker: **Bohdan Maruszewski** | Poland

14:30–14:40



Intermission

14:40–15:00



**INDUSTRY SPONSORED PRESENTATION 1** (see page 21)

15:00–15:10



Intermission

15:10–15:30



**INDUSTRY SPONSORED PRESENTATION 2** (see page 21)

15:30–15:40



Intermission

15:40–16:40



**SESSION 3: Surgical Management in DORV**

Chairs: **François Lacour-Gayet** | France, **Massimo Padalino** | Italy, **Jürgen Hörer** | Germany

15:40–15:55 *The Cardiologist's view: What to tell the surgeons*  
**Katarina Hanséus** | Sweden

15:55–16:10 *How 3D printing can help in surgical planning*  
**Eleftherios M. Protopapas** | Greece

16:10–16:25 *Surgical options in various VSD subtypes: Fallot, TGA, non-committed, remote, AVSD*  
**Mark Hazekamp** | Netherlands

16:25–16:40 *Rastelli vs REV vs Nikaidoh for DORV – PS*  
**Viktor Hraska** | USA

# Detailed Programme

## DAY 1 | Friday | 6 May 2022

Time  
indicated  
in EEST  
(UTC+3h)



**ECHSA** ANNUAL MEETING  
VIRTUAL EVENT 2022

16:40-16:50



### Intermission

16:50-17:20



### SESSION 4: SPECIAL SESSION - HONORING MARSHALL LEWIS JACOBS The WJPCS Editor's Perspective

Chairs: **Tjark Ebels** | Netherlands, **Sertaç Çiçek** | Turkey, **Rudolf Mair** | Austria

Introduction by: **Morten Helvind** | Denmark

Speaker: **Marshall Lewis Jacobs** | USA

17:20-17:30



### Intermission

17:30-18:30



### SESSION 5: ABSTRACT PRESENTATIONS

Chairs: **Zohair Alhalees** | Saudi Arabia, **Stojan Lazarov** | Bulgaria, **Katarina Hanséus** | Sweden

**OP05** *Intraoperative transit-time flow measurement of caval veins flow before and after bidirectional cavo-pulmonary anastomosis in single ventricle patients*  
**Sara Camilla Arrigoni** | Netherlands

**OP06** *Aortic Height Index as indicator of ascending aortic aneurysm in Tetralogy of Fallot*  
**Andrea Giulio Quarti** | Italy

**OP07** *Patch reconstruction of pulmonary arteries in patients with right ventricular outflow tract lesions - Influence of patch material on reintervention rate*  
**Tim Hildebrandt** | Germany

**OP08** *Prevalence, and Results of Pulmonary Valve Replacement Late after Repair of Tetralogy of Fallot (TOF) at a Single European Center and at ECHSA Congenital Database Centers*  
**Eleftherios Protopapas** | Greece

18:30-18:40



### Intermission

18:40-19:10



### INVITED HONORARY LECTURE 2

Chairs: **Andrzej Kansy** | Poland, **Anastasios Polimenakos** | USA, **Vladimir Ilyin** | Russia

Introduction by: **George Sarris** | Greece

Speaker: **James S. Tweddell** | USA



12:00–13:00



### SESSION 6: ABSTRACT PRESENTATIONS

Chairs: **Lorenzo Galletti** | Italy, **Julie Cleuziou** | Germany, **Roberto Di Donato** | Italy

- OP09** *Outcomes of the congenital heart surgery in patients less than 2.0 kg*  
**Oleg Kornoukhov** | Russian Federation
- OP10** **CASE PRESENTATION:** *Limitations of Modern Transplantology pandemic, Transplantation Andaspergillosis – Case Report*  
**Anna Danel** | Poland
- OP11** **CASE PRESENTATION:** *Rare obstructive right Coronary Arteriovenous Fistula (CAVF). A Case Report*  
**Eleftherios Protopapas** | Greece
- OP12** **VIDEO:** *Konno-Rastan aortoventriculoplasty for multilevel aortic obstruction in a patient with high postcapillary pulmonary hypertension*  
**Matej Nosal** | Slovakia

13:00–13:10



Intermission

13:10–13:40



### INVITED HONORARY LECTURE 3: Three-dimensional understanding of congenital cardiac malformations – The new gold standard

Introduction by: **Jose Fragata** | Portugal

Speaker: **Robert Anderson** | United Kingdom

13:40–13:50



Intermission

# Detailed Programme

DAY 2 | Saturday | 7 May 2022

Time  
indicated  
in EEST  
(UTC+3h)



**ECHSA** ANNUAL MEETING  
VIRTUAL EVENT 2022

13:50-15:00



## SESSION 7: Lymphatic system and intervention in congenital heart disease

Chairs: **Nikos Giannopoulos** | Greece, **Matej Nosal** | Slovakia, **Illya Yemets** | Ukraine

13:50-14:05 *The lymphatic system: an overview*  
**Vibeke E. Hjortdal** | Denmark

14:05-14:20 *Pathology of the lymphatic system*  
**Yoav Dori** | USA

14:20-14:35 *Percutaneous interventions in the lymphatic system*  
**Yoav Dori** | USA

14:35-14:50 *Surgical interventions in the lymphatic system*  
**Viktor Hraska** | USA

14:50-15:00 Discussion

15:00-15:30



## Intermission

15:30-16:10



## ECHSA COMMITTEE REPORTS & CLOSING SESSION

15:30-15:45 **ECHSA DATABASE COMMITTEE REPORT**  
Presented by: **Bohdan Maruszewski** | Poland

15:45-16:00 **ECHSA RESEARCH COMMITTEE REPORT**  
Presented by: **Vladimiro Vida** | Italy, **James St. Louis** | USA

16:00-16:10 **CLOSING SESSION – Farewell**  
Addressed by the Host: **George Sarris** | Greece

16:10-16:20



## Intermission

16:20-17:20



**ECHSA Business Meeting** | *Members only*

## Oral Presentations Catalogue

**OP01 | *Survival and re-operations following repair of truncus arteriosus – A population-based retrospective follow-up study* | Mari Ylinen, Otto Rahkonen, Olli Pitkänen-Argillander, Antti Huuskonen, Tommi Pätilä, Ilkka Mattila (Helsinki, Finland)**

**OP02 | *Mitral valve replacement in neonates and infants: a single-center experience* | Dmytro Kozhokar, Illya Yemets, Roman Sekelyk, Andrii Kurkevych (Kyiv, Ukraine)**

**OP03 | *Factors affecting Truncus arteriosus repair in the modern era* | Ahmed Abousteit, Ramesh Kutty, Rafael Guerrero, Ram Dhannapuneni, Attilio Lotto (Liverpool, United Kingdom)**

**OP04 | *Quality of life in failing Fontan patients supported with the novel EXCOR Venous Cannula: experience from the first two cases* | Oliver Miera, Daniel Zimpfer, Sebastian Michel, Nikolaus Haas, Ina Michel-Behnke, Jürgen Hörer (Berlin, Germany; Vienna, Austria; Munich, Germany)**

**OP05 | *Intraoperative transit-time flow measurement of caval veins flow before and after bidirectional cavo-pulmonary anastomosis in single ventricle patients* | Sara Camilla Arrigoni, Joost MMA van der Maaten, Marc TR Roofthoof, Roland F Hoffmann, Rolf MF Berger, Tjark Ebels (Groningen, Netherlands)**

**OP06 | *Aortic Height Index as indicator of ascending aortic aneurysm in Tetralogy of Fallot* | Andrea Giulio Quarti, Valeria Francesca Mangerini, Valentina Gesuete, Francesco Dimitri Petridis, Lucio Careddu, Emanuela Angeli, Gaetano Domenico Gargiulo (Bologna, Italy)**

**OP07 | *Patch reconstruction of pulmonary arteries in patients with right ventricular outflow tract lesions – Influence of patch material on reintervention rate* | Tim Hildebrandt, Maria von Stumm, Stanimir Georgiev, Peter Ewert, Jürgen Hörer, Julie Cleuziou (Munich, Germany)**

**OP08 | *Prevalence, and Results of Pulmonary Valve Replacement Late after Repair of Tetralogy of Fallot (TOF) at a Single European Center and at ECHSA Congenital Database Centers* | Eleftherios M. Protopapas, Andrzej Kansy, Nicolas Hakim, Zdzislaw Tobota, Bohdan Maruszewski, Georgios Sarris (Athens, Greece; Warsaw, Poland)**

**OP09 | *Outcomes of the congenital heart surgery in patients less than 2.0 kg* | Oleg Kornoukhov, Oksana Kalinina, Asiya Valitova, Svetlana Biryukova, Yuri Kornoukhov, Tatyana Antoshkina, Mihail Sokolnikov, Vladimir Iliyn (Moscow, Russia)**

**OP10 | *Limitations of Modern Transplantology pandemic, Transplantation Andaspergillosis – Case Report* Hanna Kubik, Michał Krawiec, Katarzyna Krzyżak, Anna Danel, Joanna Sliwka, Szymon Pawlak (Zabrze, Poland)**

**OP11 | *Rare obstructive right Coronary Arteriovenous Fistula (CAVF). A Case Report* | Eleftherios M. Protopapas, Nicolas Hakim, Chrysanthos Alexopoulos, George Sarris (Athens, Greece)**

**OP12 | *VIDEO: Konno-Rastan aortoventriculoplasty for multilevel aortic obstruction in a patient with high postcapillary pulmonary hypertension* | Matej Nosál, Pavel Valentik, Michal Sagat, Christos Vazaios, Fadi Sabateen (Bratislava, Slovakia)**



## e-Poster Presentations Catalogue

**PP01** | *Orthopnea due to iatrogenic perforation of the anterior mitral leaflet and aortomitral continuity, following subaortic membrane resection in a 9-year-old child* | **Spiros Loggos**, Dimos Karangelis, Kleio Laskari, Spiros Skardoutsos, Afrodite Tzifa, Fotios Mitropoulos (Athens, Greece; Alexandroupolis, Greece; London, United Kingdom)

**PP02** | *Neonatal aneurysm of the Right coronary sinus of Valsalva housing a clot* | **Spiros Loggos**, Charalampos Kavvouras, Ioannis Polymeroy, Dimos Karangelis, Spiros Skardoutsos, Afrodite Tzifa, Fotios Mitropoulos (Athens, Greece; Alexandroupolis, Greece; London, United Kingdom)

**PP03** | *Can bioprosthetic valve be an alternative for patients unsuitable for mechanical valve replacement?* | **Karol Żmudka**, Aleksandra Spychał, Błażej Ochman, Szymon Pawlak, Joanna Śliwka | (Zabrze, Poland)

**PP04** | *A 20-year follow-up of vascular patch augmentation repair for long-segment tracheal stenosis* | **Sailay Siddiqi**, Mark Hazekamp (Leiden, Netherlands)



**Zohair ALHALEES** | *WSPCHS President | King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia*

**Robert ANDERSON** | *UCL GOS Institute of Child Health, London, United Kingdom*

**Sara C. ARRIGONI** | *University Medical Center Groningen, Netherlands*

**Dimitris BERTSIMAS** | *MIT Sloan School of Management, Cambridge MA, USA*

**Sertaç ÇIÇEK** | *Mayo Clinic, Rochester MN, USA*

**Julie CLEUZIYOU** | *German Heart Centre, Munich, Germany*

**Roberto DI DONATO** | *Al Jalila Children's Specialist Hospital, Dubai, UAE*

**Yoav DORI** | *Jill and Mark Fishman Center for Lymphatic Disorders and Lymphatic Research, Children's Hospital of Philadelphia (CHOP), Philadelphia PA, USA*

**Tjark EBELS** | *University Medical Centre Groningen, Netherlands*

**Jose FRAGATA** | *Hospital de Santa Marta, Lisbon, Portugal*

**Lorenzo GALLETTI** | *Ospedale Pediatrico Bambino Gesù, Rome, Italy*

**Nikos GIANNOPOULOS** | *Onassis Cardiac Surgery Center, Athens, Greece*

**Katarina HANSÉUS** | *Skane University Hospital, Lund, Sweden*

**Mark HAZEKAMP** | *Leiden University Medical Center, Leiden, Netherlands*

**Morten HELVIND** | *Rigshospitalet, Copenhagen, Denmark*

**Claudia HERBST** | *Medical University Vienna, Austria*

**Vibeke E. HJORTDAL** | *Copenhagen University Hospital, Rigshospitalet; Institute of Clinical Medicine, Copenhagen University, Denmark*

**Jürgen HÖRER** | *German Heart Center, Munich, Germany*

**Viktor HRASKA** | *Medical College of Wisconsin, Children's Wisconsin, Milwaukee WI, USA*

**Vladimir ILYIN** | *Filatov Children's Hospital, Moscow, Russia*

**Jeffrey JACOBS** | *University of Florida, Gainesville FL, USA*

**Marshall Lewis JACOBS** | *Johns Hopkins School of Medicine, Baltimore MD, USA*

**Andrzej KANSY** | *The Children's Memorial Health Institute, Warszawa, Poland*

**François LACOUR-GAYET** | *Mecénat Chirurgie Cardiaque Foundation, Paris, France*

**Stojan LAZAROV** | *National Heart Hospital, Sofia, Bulgaria*

**Attilio LOTTO** | Alder Hey Children's Hospital, Liverpool, United Kingdom

**Rudolf MAIR** | Kepler University Clinicum, Linz, Austria

**Bohdan MARUSZEWSKI** | Children's Memorial Health Institute, Warsaw, Poland

**Ilkka MATTILA** | New Children's Hospital, Helsinki University, Finland

**Matej NOSAL** | Children's Heart Centre, Bratislava, Slovakia

**Massimo PADALINO** | University of Padova, Italy

**Anastasios POLIMENAKOS** | The Heart Center for Congenital Heart Disease Children's Hospital of Georgia, Augusta GA, USA

**Eleftherios M. PROTOPAPAS** | Mitera Children's Hospital, Athens, Greece

**George SARRIS** | Athens Heart Surgery Institute and Iaso Children's Hospital, Athens, Greece

**James ST. LOUIS** | Children's Hospital of Georgia, Augusta GA, USA

**James S. TWEDDELL** | UC Department of Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati OH, USA

**Vladimiro VIDA** | University of Padova, Italy

**Illya YEMETS** | Ukrainian Children's Cardiac Center, Kiev, Ukraine

The ECHSA 2022 Annual Meeting gratefully acknowledges the support of the below industry:

Silver Sponsor



Supporter





## **BERLIN HEART**

<http://www.berlinheart.de>

Berlin Heart GmbH develops, manufactures, and markets innovative ventricular assist devices (VADs) for mechanical circulatory support. With the EXCOR® Adult\* and the EXCOR® Pediatric, Berlin Heart is the only company in the world able to provide support to patients of every age and size, from infants to adults, thereby meeting an important worldwide unmet need.

Berlin Heart's systems provide left ventricular, right\* ventricular, or biventricular support (both sides); hospitals around the world use the system for short-, medium-, and long-term circulatory support, providing patients with a life-saving treatment option.

Users can also access round-the-clock medical and technical support.

(\*EXCOR® Adult and EXCOR® as RVAD are not FDA approved.)



## **MEDTRONIC**

<https://www.medtronic.com/>

We lead global healthcare technology, boldly attacking the most challenging problems. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ people, and our technologies transform the lives of two people every second, every hour, every day. Expect more from us.

Medtronic. **Engineering the extraordinary.**



## **CARDIO INNOVATION S.A.**

Cardio Innovation S.A. constitutes a recognized Greek company. It was founded by a team of experienced professionals in Health Care. The company is headquartered in Athens, Greece and It was founded in February 2015. Since then, we have been active in the field of cardiac surgery, providing a diverse product portfolio.

The experience, the know-how and the continuous specialization have led our company to a remarkable growth over the last 3 years, that makes us a strong, uprising medical technology and services company.

Our exclusive collaboration with world-class manufacturers in the research and production of implantable and non-implantable products ensures maximum support to the patient, with the natural consequence the more effective and efficient management of many cardiac surgery interventions.

**Friday, 6 May 2022**

Time indicated in EEST (UTC+3h)

**14:40-15:00 INDUSTRY SPONSORED PRESENTATION 1**

**EXCOR® Revive - shift of perspective for failing Fontan patients?**

Speakers:

**Jürgen Hörer** (German Heart Center, Munich, Germany)

**Michael Hübler** (University Medical Center Hamburg-Eppendorf – UKE, Germany)

**Daniel Zimpfer** (Vienna General Hospital, Austria)

Sponsored by



**15:00-15:10**

**INTERMISSION**


**15:10-15:30 INDUSTRY SPONSORED PRESENTATION 2**

**Temporal changes in surgical management of tetralogy of Fallot and timing of pulmonary valve replacement**

Speaker:

**Mathis Gröning** (Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark)

Sponsored by



# EXCOR® ACTIVE

## *Mobile Driving Unit for Explorers*

- ✓ Mobility for every age group
- ✓ Battery runtime of min. 6.5 hours
- ✓ Compact, light and robust design
- ✓ Family time for parents and children
- ✓ Let's get out of here and enjoy the sunny weather!

„Now the parents can just go for a walk with their kids! Trips to the cafeteria or a walk in the fresh air are now possible. A giant step towards a better quality of life for everyone.“

Prof. Dr. Nikolaus Haas  
LMU University Hospitals Munich



Learn more about  
**EXCOR® Active**

EXCOR® Active is not FDA approved.





# EXCOR® Revive

## *Build a Bridge to heart transplant for Failing Fontan Patients*

The EXCOR® Revive concept generates pulsatile pulmonary blood flow to improve hemodynamics.

Therefore, EXCOR® Revive intends to improve the end-organ function and condition of failing Fontan patients.



“Optimal positioning of the cannula in the specific Fontan anatomy significantly improves the outcome.”

(Prof. Dr. med. Jürgen Hörer, First EXCOR® Revive UVAD implantation)

“The surgical complexity is drastically reduced.”

(Prof. Dr. med. Daniel Zimpfer, First EXCOR® Revive BVAD implantation)

“Lower mortality and morbidity on the waiting list.”

(Prof. Dr. med. Nikolaus Haas)

“It is a game changer for failing Fontan patients.”

(Prof. Dr. med. Eugen Sandica)

**Build a Bridge to Transplant.**

**Build a Bridge to Life!**

# Medtronic

## Excellent valve durability with low intervention rates comparable to surgery

Discover more



Melody™  
TPV

Freedom from surgical intervention on the originally implanted valve was **87%** for both Melody TPV and SPVR at **10 years**<sup>1</sup>

#### Reference

<sup>1</sup>Georgiev S, Ewert P, Eicken A, et al. Munich Comparative Study: Prospective Long-Term Outcome of the Transcatheter Melody Valve Versus Surgical Pulmonary Bioprosthesis With Up to 12 Years of Follow-Up. *Circ Cardiovasc Interv.* July 2020;13(7):e008963.